S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY

• D. Papazoglou,
• L. Ysebaert,
• N. Ioannou,
• B. Apollonio,
• P. Patten,
• S. Herter,
• M. Bacac,
• A. Deutsch,
• C. Klein,
• A. Vardi,
• A. Quillet-Mary,
• A. Ramsay

Affiliations

D. Papazoglou

1 Hemato-oncology, King’s College London, London, United Kingdom

L. Ysebaert

2 Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

N. Ioannou

1 Hemato-oncology, King’s College London, London, United Kingdom

B. Apollonio

1 Hemato-oncology, King’s College London, London, United Kingdom

P. Patten

3 King’s Health Partners, King’s College Hospital, London, United Kingdom

S. Herter

4 Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Zurich, Switzerland

M. Bacac

4 Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Zurich, Switzerland

A. Deutsch

5 Medical University of Graz, Graz, Austria

C. Klein

4 Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Zurich, Switzerland

A. Vardi

6 Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece

A. Quillet-Mary

2 Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

A. Ramsay

1 Hemato-oncology, King’s College London, London, United Kingdom